Lynn Heasley

Professor and Chair

University of Colorado Anschutz Medical Campus
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (5)

Background: ALK-positive NSCLC derives limited benefit from immune checkpoint inhibitors, yet PD-L1 expression is frequently elevated at diagnosis. Its relevance to ALK tyrosine kinase inhibitor (TKI) efficacy remains unclear. We investigated the association between PD-L1 expression and first-line ALK TKI outcomes using clinical data and preclinical models.Methods: Clinical and molecular data were evaluated for patients with ALK-rearranged NSCLC at the University of Colorado. PD-L1 was assessed by tumor proportion score (TPS). Murine EML4–ALK cell lines were engineered to overexpress PD-L1 to evaluate TKI response in vitro and in immune-competent models.Results: Among 130 TKI-naïve patients, 57 (44%) had high PD-L1 (TPS ≥50%) and 73 (56%) had low PD-L1 (TPS <50%). After multivariable adjustment, high PD-L1 was associated with significantly shorter progression-free survival (PFS) compared with low PD-L1 (11 vs. 21 months; HR 2.29, 95% CI 1.51–3.49; p < 0.001), but no difference in overall survival (91 vs. 107 months; HR 1.16, 95% CI 0.62–2.17). Objective response rates were similar (81.8% vs. 83.3%; r = -0.20). In preclinical models, tumor cell PD-L1 overexpression did not alter alectinib sensitivity, depth, or durability of response in vitro or in vivo. High PD-L1 expression in patient biopsies correlated with increased neutrophil content.Conclusions: High PD-L1 expression is a negative predictive marker for response durability to first and second generation ALK TKIs without affecting initial radiographic response. Preclinical findings suggest PD-L1 does not directly impair TKI efficacy through cell-intrinsic signaling, suggesting that tumor microenvironment-mediated mechanisms may contribute to the reduced durability of response.

Year:

2026

Residual disease remains a major obstacle for achieving durable responses in patients treated with oncogene-targeted therapy. Drug-tolerant persister (DTP) cells emerging under treatment and persisting in residual tumors are considered to be the root of acquired resistance, yet their contribution to immune evasion in on-treatment tumors is poorly defined. Here, we show in the context of EGFR-mutant lung cancer that DTP cells actively contribute to the formation of an immunosuppressive tumor microenvironment during EGFR tyrosine kinase inhibitor (TKI) therapy. In syngeneic mouse models and in patients, EGFR TKI therapy leads to an accumulation of immunosuppressive macrophages, which is strictly treatment-dependent and fully reversible upon treatment cessation or progressive disease, respectively. Quiescent DTP cells directly drive the recruitment and immunosuppressive reprogramming of monocytes and macrophages through a YAP-driven secretome, and the DTP-reprogrammed monocytes suppress T cell proliferation and effector functions in vitro . Co-targeting YAP with a TEAD inhibitor ORM-47286 rewires the DTP secretome and inhibits macrophage reprogramming in vitro , and prevents immunosuppressive macrophage accumulation and improves the efficacy of EGFR TKI therapy in immunocompetent mouse models. Our findings highlight the previously unappreciated role of DTP cells in modulating the tumor microenvironment in on-treatment tumors, and position the treatment-induced YAP/TEAD activity in DTP cells as an important driver of adaptive immunosuppression during EGFR-targeted therapy.

Year:

2026

The application of personalized medicine to lung adenocarcinoma has resulted in new therapies based on specific oncogenic drivers that have improved patient outcomes. However, oncogene-defined subsets of patients exhibit a significant heterogeneity of response to these agents. Defining the factors that mediate the varied depth and duration of response are critical to developing new therapeutic strategies. While the examination of patient samples can provide important correlations, definitive mechanistic studies require the use of relevant preclinical models. Based on a large body of data, interactions between cancer cells and the surrounding tumor microenvironment, comprised of inflammatory, immune, and vascular cells, represent a critical determinant of therapeutic response. In this review, we focus on preclinical models that can be used to explore these interactions, identify new therapeutic targets, and test combination therapies. In particular, we will describe the use of implantable orthotopic immunocompetent models employing a panel of murine lung adenocarcinoma cell lines with oncogenic drivers common to human lung adenocarcinoma as a powerful system to develop new treatment approaches.

Year:

2025

Head and Neck Squamous Cell Carcinoma (HNSCC) is a deadly cancer with poor response to targeted therapy, largely driven by an immunosuppressive tumor microenvironment (TME). Here we examine the immune-modulatory role of the receptor tyrosine kinase EphA4 in HNSCC progression. Within the TME, EphA4 is primarily expressed on regulatory T cells (Tregs) and macrophages. In contrast ephrinB2, an activating ligand of EphA4, is expressed in tumor blood vessels. Using genetically engineered mouse models, we show that EphA4 expressed in Tregs promotes tumor growth, whereas EphA4 expressed in monocytes inhibits tumor growth. In contrast, ephrinB2 knockout in blood vessels reduces both intratumoral Tregs and macrophages. A novel specific EphA4 inhibitor, APY-d3-PEG4, reverses the accelerated tumor growth we had previously reported with EphB4 cancer cell knockout. EphA4 knockout in macrophages not only enhanced their differentiation into M2 macrophage but also increased Treg suppressive activity. APY-d3-PEG4 reversed the accelerated growth seen in the EphA4 knockout of monocytes but conferred no additional benefit when EphA4 was knocked out on Tregs. Underscoring an EphA4-mediated interplay between Tregs and macrophages, we found that knockout of EphA4 in Tregs not only decreases their activation but also reduces tumor infiltration of pro-tumoral M2 macrophages. These data identify Tregs as a primary target of APY-d3-PEG4 and suggest a role for Tregs in regulating macrophage conversion. These data also support the possible anti-cancer therapeutic value of bispecific peptides or antibodies capable of promoting EphA4 blockade in Tregs but not macrophages. Significance EphA4 in regulatory T cells has a pro-tumoral effect while EphA4 in macrophages plays an anti-tumoral role underscoring the necessity of developing biologically rational therapeutics.

Year:

2024

Year:

2023

Collaborators (8)

Heidi Haikala

Professor

University of Helsinki

FINLAND
View details

Paloma Cejas

Head of Innovation/Director

Dana-Farber Cancer Institute

UNITED STATES
View details

Anthony J. Saviola

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

Milos Gojkovic

University of Helsinki

FINLAND
View details

Maija Hollmén

Principal Investigator

University of Turku

FINLAND
View details

Tejas Patil

Assistant Professor

University of Colorado School of Medicine

UNITED STATES
View details

Raphael Nemenoff

Professor

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

Steffen Boettcher

Assistant professor

University Hospital of Zurich

SWITZERLAND
View details